Raiffeisen Bank International’s Telix Pharmaceuticals TLX Stock Holding History

Raiffeisen Bank International’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.16M	Buy	+130,000	New	+$990K	0.02%	371

Other funds holding TLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PIC

Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Raiffeisen Bank International's TLX Position: Q1 2026 in Review

Raiffeisen Bank International opened a new position in Telix Pharmaceuticals (TLX) in Q1 2026: 130,000 shares worth $1.16M. The stake represents 0.02% of the portfolio and ranks #371 among its holdings.

39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

Raiffeisen Bank International held 130,000 shares of Telix Pharmaceuticals worth $1.16M as of Q1 2026.
Telix Pharmaceuticals was a new Raiffeisen Bank International position in Q1 2026.
Telix Pharmaceuticals made up 0.02% of Raiffeisen Bank International's portfolio in Q1 2026, its #371 holding.
39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Raiffeisen Bank International's 13F filing for Q1 2026, filed 24 Apr 2026.